GLP-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | 31 amino acids |
| Backbone modification | Aib at position 8 | Blocks DPP-4 cleavage |
| Fatty acid chain | C18 diacid | Supports albumin binding |
| Native half-life | 1 to 2 minutes | Endogenous GLP-1 |
| Analog half-life | Approximately one week | Extended by albumin binding |
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
== Clinical Practice & Patient Care == AMP publishes evidence-based guidelines and freely available reports to provide best practices and recommendations, and to highlight the developments and changing practices in its rapidly evolving field. AMP frequently collaborates with other well-respected professional organizations, such as the College of American Pathologists (CAP), American Society of Clinical Oncology (ASCO), American College of Obstetricians and Gynecologists (ACOG) and American College of Medical Genetics and Genomics (ACMG) to share expertise and broaden the reach of various publications. Guidelines are authored by AMP members elected to the Clinical Practice Committee or appointed by the Board of Directors as subject matter experts to specific working groups.
The exchange of a protecting group from a methyl ether to a MOM-ether inhibits here the opening of an epoxide to an aldehyde. Protecting group chemistry finds itself an important application in the automated synthesis of peptides and nucleosides. The technique was introduced in the field of peptide synthesis by Robert Bruce Merrifield in 1977. For peptide synthesis via automated machine, the orthogonality of the Fmoc group (basic cleavage), the tert‑butyl group (acidic cleavage) and diverse protecting groups for functional groups on the amino acid side-chains are used. Up to four different protecting groups per nucleobase are used for the automated synthesis of DNA and RNA sequences in the oligonucleotide synthesis. The procedure begins actually with redox chemistry at the protected phosphorus atom. A tricoordinate phosphorus, used on account of the high reactivity, is tagged with a cyanoethyl protecting group on a free oxygen. After the coupling step follows an oxidation to phosphate, whereby the protecting group stays attached. Free OH-groups, which did not react in the coupling step, are acetylated in an intermediate step. These additionally-introduced protecting groups then inhibit, that these OH-groups might couple in the next cycle.
== Production == Although glycine can be isolated from hydrolyzed proteins, this route is not used for industrial production, as it can be manufactured more conveniently by chemical synthesis. The two main processes are amination of chloroacetic acid with ammonia, giving glycine and hydrochloric acid, and the Strecker amino acid synthesis, which is the main synthetic method in the United States and Japan. About 15 thousand tonnes are produced annually in this way. Glycine is also co-generated as an impurity in the synthesis of EDTA, arising from reactions of the ammonia co-product.
Sources: en.wikipedia.org
=== Burnup === "Burnup" is a measure of how much energy has been extracted from a given mass of heavy metal in fuel, often expressed (for power reactors) in terms of gigawatt-days per ton of heavy metal. Burnup is an important factor in determining the types and abundances of isotopes produced by a fission reactor. Burnup is distinct from the conversion or breeding ratio. A 2003 study of reduced-moderation water reactor fuel assemblies reported a configuration with an average core burnup of 38.2 GWd/t and a conversion ratio of 1.0, and another with 45 GWd/t and a conversion ratio of 0.97. In the past, breeder-reactor development focused on reactors with low breeding ratios, from 1.01 for the Shippingport Reactor running on thorium fuel and cooled by conventional light water to over 1.2 for the Soviet BN-350 liquid-metal-cooled reactor. Theoretical models of breeders with liquid sodium coolant flowing through tubes inside fuel elements ("tube-in-shell" construction) suggest breeding ratios of at least 1.8 are possible on an industrial scale. The Soviet BR-1 test reactor achieved a breeding ratio of 2.5 under non-commercial conditions.
=== Honorary doctorates === Duterte declined an honorary doctor of laws degree offered by the University of the Philippines amid opposition from members of the university. Duterte was conferred an honorary doctorate degree for international relations or foreign diplomacy from the Moscow State Institute of International Relations on October 5, 2019. Duterte received an honorary Juris Doctor degree from his alma mater, San Beda College of Law in November 2023.
== Structure == OcDH is a monomer with a molecular weight of 38kD made of two functionally distinct subunits. The first, Domain I, is composed of 199 amino acids and contains a Rossmann fold. Domain II is composed of 204 amino acids and is connected to the Rossmann fold of Domain I via its N-terminus.
Sources: en.wikipedia.org
isoform.io is a database of AlphaFold2-generated structures of proposed splice isoforms in the human genome. It includes information from 237,275 human transcripts. It has been used to detect errors in the mRNA predictions for a handful of genes. AlphaFold has shown certain limitations. AlphaFold DB provides models of individual protein chains (monomers), rather than their biologically relevant complexes. Many protein regions are predicted with low confidence score, including the intrinsically disordered protein regions. Alphafold-2 was validated for predicting effects of point mutations on structure and free energy, with a partial success.
The tertiary structure and topology of TMEM125 was predicted and visualized through Phyre2. TMEM125 has 1 predicted phosphorylation site (CK2 Phos), 5 predicted N-myristoylation sites (N-myr), 2 predicted palmitoylation sites (Pal), and 1 predicted amidation site (Amid). It also contains the domain of unknown function 66 (DUF66). TMEM125 is predicted to be subcellularly localized in the plasma membrane. It is secondarily predicted to be localized in the endoplasmic reticulum. There were no scientifically-verified protein interactions identified for TMEM125. String Protein Interaction predicted 10 functional protein partners for TMEM125, but all were determined through textmining. TMEM125 is conserved in species as distantly related to humans as cartilaginous fish, that’s most recent common ancestor to humans existed 465 million years ago. TMEM125 is highly conserved in primates, mammals, birds, reptiles, bony fish, and cartilaginous fish, but is not observed in invertebrates. TMEM125 does not have any paralogs.
Americium has been produced in small quantities in nuclear reactors for decades, and kilograms of its 241Am and 243Am isotopes have been accumulated by now. Nevertheless, since it was first offered for sale in 1962, its price, about US$1,500 per gram (US$43,000/oz) of 241Am, remains almost unchanged owing to the very complex separation procedure. The heavier isotope 243Am is produced in much smaller amounts; it is thus more difficult to separate, resulting in a higher cost of the order US$100,000–US$160,000 per gram (US$2,800,000–US$4,500,000/oz). Americium is not synthesized directly from uranium – the most common reactor material – but from the plutonium isotope 239Pu. The latter needs to be produced first, according to the following nuclear process:
Sources: en.wikipedia.org
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.
A fatty acid side chain attaches the peptide to serum albumin, which shields it from kidney filtration and protease activity. This interaction is the main reason its circulation time is extended.
No. The native hormone is GLP-1, and semaglutide is an engineered variant with three deliberate structural alterations. It does not appear in unmodified biological sources.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.